Kopran: Uncertain Future - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Kopran: Uncertain Future

Sep 6, 2001

Kopran, promoted by Parijat Enterprise, is one of the integrated domestic pharmaceutical players. Its products Aten (cardiovascular), Vent (respiratory) and Smyle enjoy strong brand equity. The company is in the midst of business and financial restructuring. The company is trying to change the perception and business profile from that of a commodity bulk manufacturer and supplier to a formulations based company with an ability to create strong brands. In the first phase of restructuring process the company hived off of its penicillin based bulk business into a separate company (KDL Biotech). In the second phase, the OTC business of privately owned Kopran Pharmaceuticals Ltd. was merged with Kopran Ltd. The company intends to focus on the OTC segment and so far the company's brand 'Smyle' has created strong brand equity.

As per recent reports, Kopran is in talks with several pharmaceutical companies for sale of its formulations business or its 'Aten' brand in the cardiovascular segment. This comes as a surprise as bulk of company’s revenues in the formulations business come from the ‘Aten' brand. This could be due to the fact that the financial situation of the company is precarious with high debt levels. The debt/equity ratio is already alarming at 1.2:1. The financial performance of the company is also fluctuating.

Kopran-Rising Interest Burden
Quarter Ended 30/9/0031/12/0031/3/0130/6/01
Sales (Rs. Mn.)529568607478
Operating Margin (%)20%20%12%25%
Interest Burden (Rs.Mn.)51528078
PBT (%)9%8%4%4%

At the current market price of Rs 40 the stock is trading at 7x its 1QFY02 earnings. In wake of the recent development regarding the proposed sale of its formulation business, the future business plan of the company remains uncertain. It is likely that the company would concentrate purely on the OTC segment where it will have to work hard to establish strong brands.

Equitymaster requests your view! Post a comment on "Kopran: Uncertain Future". Click here!

  

More Views on News

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)

Aug 16, 2021

The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

Cipla Shares Tank Despite Strong Earnings (Views On News)

Aug 6, 2021

The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.

Glenmark Life Sciences Makes Lacklustre Debut. Shares List At 4% Premium (Views On News)

Aug 6, 2021

Glenmark Life Sciences' IPO had received strong response from investors as the offer was subscribed 44.17 times.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider (Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore (Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market (Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race (Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

How to Create a Second Income from Trading (Profit Hunter)

Sep 10, 2021

My trading system that works in all kinds of markets.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS